Multiple developments in delivery formulations and the chemical structure of the oligonucleotides were made to enhance siRNA efficacy in targeting oncogenic KRAS in lung, colon, and pancreatic cancer cells. Here, KRAS is linked to familial pancreatic carcinoma.